Anixa Biosciences ANIX 深 沪
等待开盘 10-10 09:30:00 美东时间
4.92
+0.480
+10.81%
华盛通- 最 高4.98
- 今 开4.40
- 成交量 73.68万股
- 最 低 4.30
- 昨 收 4.44
- 总市值 1.62亿
- 52周最高 4.98
- 市盈率 静 --
- 换手率 2.24%
- 52周最低 2.07
- 委 比 -57.77%
- 总股本 3291.69万
- 历史最高 8.09
- 量 比 1.83
- 振 幅 15.32%
- 历史最低 1.33
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
Anixa Biosciences Completes The Final Patient Visit In Its Phase 1 Breast Cancer Vaccine Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of the final patient visit in its breast cancer
10-07 20:46
Anixa To Present Phase 1 Breast Cancer Vaccine Data At 2025 San Antonio Breast Cancer Symposium
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and PreventionComprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Discussions and Advance
09-22 20:09
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
Anixa Biosciences Q3 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19.54 percent. This is a 30 percent increase over losses of $(0.10) per share from
09-11 04:36
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Anixa Biosciences Completes Dosing Of Fourth Cohort In Ongoing Phase 1 Clinical Trial Evaluating FSHR-Targeted CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
Continue to observe a positive safety profile—no dose limiting toxicities, cytokinerelease syndrome or immune effector cell-associated neurotoxicitySAN JOSE, Calif., Sept. 8, 2025 /PRNewswire/ -- Anixa Biosciences,
09-08 20:09
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (N...
08-12 20:05
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
Annexon, Inc. announced that its vonaprument (formerly ANX007) has been selected by the European Medicines Agency (EMA) to participate in the Product Development Coordinator (PDC) pilot, aimed at streamlining regulatory interactions and evidence planning. Vonaprument, a first-in-kind antibody fragment targeting C1q in the eye, has the potential to become the first approved treatment for dry age-related macular degeneration (AMD) with geographic a...
08-07 20:30
